UNICREDIT BANK/CALL/BIOGEN IDEC/300/0.1/17.12.25 | Real-time Bid/Ask 04:03:53 26/06/2024 pm IST | ||
| 2.01 EUR / 2.09 EUR | 0.00% |
|
| Current month | -11.26% | ||
| 1 month | -2.84% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 26/24/26 | 2 | -2.44% |
| 25/24/25 | 2.05 | -5.53% |
| 24/24/24 | 2.17 | +5.34% |
| 21/24/21 | 2.06 | -3.74% |
| 20/24/20 | 2.14 | +5.94% |
Delayed Quote Börse Stuttgart
Last update June 26, 2024 at 02:36 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | 
UniCredit
|
| WKN | HD1H9M |
| ISIN | DE000HD1H9M1 |
| Date issued | 28/12/2023 |
| Strike | 300 $ |
| Maturity | 17/12/2025 (540 Days) |
| Parity | 10 : 1 |
| Emission price | 4.11 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.27 € |
|---|---|
| Lowest since issue | 1.11 € |
| Spread | 0.08 € |
| Spread % | 3.85% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
35
Last Close Price
223.2
USD
Average target price
283.2
USD
Spread / Average Target
+26.87%
- Stock Market
- Warrants
- Warrant
